Early Results of BetterLife Preclinical Study Show AP-003 (rhIFN⍺2b) Provides Up to 97% Protection in Human Cells Against the Delta Variant of SARS-CoV-2

Your email address will not be published. Required fields are marked *

Save my name, email, and website in this browser for the next time I comment.

Post Comment